Nasus Pharma Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $41.0M
- Price
- $3.85
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.26%
- Volume
- 11.2K
About
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Quick stats
Shares outstanding11.7M
Computed float6.4M
Float / shares55.0%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002029039
Websitehttps://www.nasuspharma.com
AI Summary
AI-generated1/23
standardneutralexecutive change
Nasus Pharma Announces Transition of Chief Financial Officer
Nasus Pharma announced that Chief Financial Officer Eyal Rubin will be leaving the company on September 18, 2026, to pursue an opportunity outside the life sciences industry.
Oren Elmaliach, the Company's Director of Finance, has been appointed Interim CFO effective immediately. Mr. Rubin will remain with Nasus through his departure date to assist with the transition.
Mr. Elmaliach is a certified public accountant with more than 15 years of experience and has been with the company since its inception.
Red flags
- CFO departing without a permanent successor named